A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
Daisuke Sakai(Osaka International Cancer Institute), Toshihiko Doi(National Cancer Center Hospital East), Volker Wacheck(Taiho Oncology (United States)), Kazunori Uenaka(Eli Lilly (Japan)), Sameera R. Wijayawardana(Eli Lilly (United States)), Yeul Hong Kim(Seoul National University Bundang Hospital), Shigenori Kadowaki(Aichi Cancer Center), Yoshito Komatsu(Hokkaido University Hospital), Se Hoon Park(Samsung Medical Center), Do‐Youn Oh(Seoul National University Hospital), Akihito Tsuji(Kagawa University Hospital), Ayuko Yamamura(Eli Lilly (Japan)), Hyun Cheol Chung(Yonsei University), Xuejing Wang(University of Bern), Yoon‐Koo Kang(Ulsan College)
Cited by 31
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k